A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
ACT Cabergoline,Dostinex, APO Cabergoline
Synonyms :
cabergoline
Class :
Hyperprolactinemia, Dopamine agonist
Dosage Forms & Strengths
tablet
0.5mg
Initial dose:0.25mg orally twice a week
Can increase by 0.25mg every four weeks up to 1mg twice a week
Safety and efficacy not established
Refer adult dosing
acrivastine and pseudoephedrineÂ
may increase the vasoconstrictive effect of alpha/beta agonists
may decrease the vasodilatory effect when combined with nitroglycerin
may enhance the risk of hypertension when combined with cabergoline
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
they increase the effect of vasoconstriction of alpha-1 agonists
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may decrease the therapeutic effect of cabergoline
may decrease the therapeutic effect of cabergoline
may decrease the therapeutic effect of cabergoline
may decrease the therapeutic effect of cabergoline
may decrease the therapeutic effect of cabergoline
may increase the toxic effect of ergot derivatives
may increase the toxic effect of ergot derivatives
may increase the toxic effect of ergot derivatives
may increase the vasoconstricting effect of ergot derivatives
may decrease the therapeutic effect of cabergoline
it decreases the effects of antipsychotic agents
it decreases the effects of antipsychotic agents
it decreases the effects of antipsychotic agents
it decreases the effects of antipsychotic agents
it decreases the effects of antipsychotic agents
may have an increased vasoconstricting effect when combined with alpha1-agonists
it decreases the efficacy of metoclopramide
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
Could potentially reduce the therapeutic efficacy of antipsychotic agents
Could potentially reduce the therapeutic efficacy of antipsychotic agents
Could potentially reduce the therapeutic efficacy of antipsychotic agents
Could potentially reduce the therapeutic efficacy of antipsychotic agents
Could potentially reduce the therapeutic efficacy of antipsychotic agents
cabergoline: they may increase the hypotensive effect of blood viscosity reducing agents
cabergoline: they may increase the hypotensive effect of blood viscosity reducing agents
may have an increased vasoconstricting effect when combined with alpha1-agonists
it decreases the effect of antipsychotic agents
it decreases the effect of metoclopramide
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may increase the vasoconstriction effect of sympathomimetic drugs
may increase the vasoconstriction effect of sympathomimetic drugs
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the therapeutic effect of antipsychotic agents
may enhance the serum concentration of CYP3A4 inhibitors
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists (Triptans)
may enhance the concentration of serum when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with dihydroergotamine
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may have an increasingly adverse effect when combined with ergot derivatives
may have an increasingly adverse effect when combined with ergot derivatives
may have an increased serotonergic effect when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
ergot derivatives increase the toxicity of bromocriptine
it increases the concentration of ergot derivatives in serum
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
dopamine agonists' efficacy will decrease when metoclopramide is used in combination
the efficacy of dopamine agonists will be decreased when sulpride is used in combination
the levels of cabergoline may be increased
ergot Derivatives may enhance the serotonergic effect of serotonergic Agents
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
may increase the serum concentration of cabergoline
may increase the serotonergic effect of ergot derivatives
may increase the vasoconstricting effect of ergot derivatives
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may have an increased serotonergic effect when combined with serotonergic agents
it increases the toxicity of calcium channel blockers cabergoline
it increases the toxicity of calcium channel blockers cabergoline
it increases the toxicity of calcium channel blockers cabergoline
it increases the toxicity of calcium channel blockers cabergoline
it increases the toxicity of calcium channel blockers cabergoline
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
When cabergoline is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
When cabergoline is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when cabergoline is used together with fencamfamin
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
When cabergoline is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When alprazolam and cabergoline is used together, this leads to reduction in the alprazolam’s metabolism
When chlordiazepoxide is used together with cabergoline, this leads to enhanced risk or seriousness of CNS depression
When cabergoline is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with cabergoline, this leads to enhanced risk or seriousness of CNS depression
When cabergoline is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When cabergoline is used together with oleandomycin, this leads to enhanced concentration serum of cabergoline
When cabergoline is used together with patupilone, this leads to enhanced concentration serum of cabergoline
When cabergoline is used together with ridaforolimus, this leads to enhanced concentration serum of cabergoline
cabergoline: it may increase the risk of methemoglobinemia with ambroxol
cabergoline: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the serum concentration of sulfamethoxazole
it may increase the effect of serotonergic agents
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the vasoconstrictive effect of beta blockers
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the serum concentration
may increase the vasoconstricting effect
may have an increasingly adverse effect when combined with ergot derivatives
may have an increased hypertensive effect when combined with ergot derivatives
it increases the effect of hypertension of ergot derivatives
may enhance the serum concentration of Ergot Derivatives
may have an increasingly adverse effects when combined with cabergoline
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Vasodilators
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
the side effects of dopamine agonists are increased with bromopride when combined
side effects of bupropion are increased when dopamine agonist is combined
side effects of dopamine agonists are increased with solriamfetol when combined
the therapeutic effect of cabergoline may be reduced
the serum levels of cabergoline may be increased
Mechanism of action
The action of cabergoline stimulates the dopamine receptors in the pituitary gland, reducing the secretion of prolactin from the lactotroph cells. This reduction in prolactin secretion is responsible for the drug’s therapeutic effects in hyperprolactinemia and other conditions associated with elevated prolactin levels
In Parkinson’s disease, cabergoline works by enhancing the effect of dopamine in the brain and improving the symptoms of the disease, such as tremors, rigidity, and bradykinesia
Spectrum
It has a broad spectrum of activity, which is why it treats various conditions. In addition to hyperprolactinemia and Parkinson’s disease, cabergoline has also been used to treat infertility, uterine fibroids, and obsessive-compulsive disorder
Frequency defined:
>10%
headache (26%)
nausea (27%)
dizziness (15%)
1-10%
fatigue (7%)
somnolence (5%)
depression (3%)
nervousness (2%)
breast pain (1%)
hot flashes (1%)
constipation (10%)
asthenia (9%)
abdominal pain (5%)
postural hypotension (4%)
dyspepsia (2%)
abnormal vision (1%)
dysmenorrhea (1%)
paresthesia (1%)
<1%
fibrosis
valvulopathy
pleural effusion
aggression
gastric ulcer
psychosis
Post-marketing reports
increased libido and pathological gambling
hypersexuality
Contraindications:
Hypersensitivity
Cardiac Valvular Disorders
Uncontrolled Hypertension
Cautions:
Hypotension
Liver Impairment
Cardiovascular Monitoring
Psychiatric Disorders
Pregnancy category: B
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Cabergoline may sometimes influence mood and motor control of patient. D2 receptor is linked with Gi proteins to inhibit adenylyl cyclase in lactotrophs cells.
Pharmacodynamics:
High amount of dopamine is present in mesolimbic pathways of brain to cause hallucinations and delusions feeling in schizophrenia patients. There is five dopamine receptor types are identified from two dopaminergic sub-families.
Pharmacokinetic:
Absorption:
It is well absorbed from the gastrointestinal tract.
Distribution:
It is distributed throughout the body with large volume of distribution.
Metabolism:
It is metabolized through hepatic pathway.
Excretion and elimination:
It shows renal clearance up to 0.08 L/min.
It is available in oral dosage form.
Generic Name: cabergoline
Why do we use cabergoline?
Cabergoline is indicated in the treatment of hyperprolactinemia.
It is used to manage Parkinsonian Syndrome symptoms with levodopa in early and advanced stages.
It is used to reduce the size of prolactin-secreting pituitary adenoma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
